Travaux scientifiques

Doç. Dr. Senem Maral

152 publications. La source de l’information est indiquée à côté de chaque publication.

Retour au profil

  1. Universal Use of Novel Oral Anticoagulant Prophylaxis in Myeloma Patients Undergoing IMiD-Based Therapy: Real-World Experience

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15020453 PMID 41598391 2 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  2. Real-World Experience with Belinostat in the Treatment of Relapsed/Refractory Peripheral T-Cell Lymphoma

    Annals of Medical Research, 2026

    DOI 10.5455/annalsmedres.2025.07.193 Texte intégral en libre accèsSource : OpenAlex

  3. A Multi-Targeted Strategy for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: Real-World Outcomes of the ViPOR Regimen

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15145401 PMID 42513315 Texte intégral en libre accèsSource : OpenAlex

  4. Enterovirus Encephalitis Developing After Treatment for Follicular Lymphoma: A Case Report

    SN Comprehensive Clinical Medicine, 2026

    DOI 10.1007/s42399-026-02560-z Source : OpenAlex

  5. Real-World Effectiveness and Renal Safety of Foscarnet for CMV Reactivation After Allogeneic Hematopoietic Stem Cell Transplantation

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15166365 PMID 42652768 1 citation (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  6. Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy

    New England Journal of Medicine, 2026

    DOI 10.1056/nejmoa2603870 PMID 42212933 7 citations (Europe PMC) Source : OpenAlex

  7. Talquetamab–Daratumumab in Relapsed or Refractory Myeloma

    New England Journal of Medicine, 2026

    DOI 10.1056/nejmoa2604657 PMID 42294841 8 citations (Europe PMC) Source : OpenAlex

  8. MajesTEC-9: A phase 3 randomized study of teclistamab monotherapy vs investigator’s choice of pomalidomide, bortezomib, and dexamethasone or carfilzomib and dexamethasone (PVd/Kd) in patients (pts) with relapsed refractory multiple myeloma (RRMM).

    Journal of Clinical Oncology, 2026

    DOI 10.1200/jco.2026.44.16_suppl.7507 Source : OpenAlex

  9. POSTER: MM-593: Phase 3 Randomized Study of Talquetamab + Daratumumab ± Pomalidomide vs Daratumumab + Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: MonumenTAL-3

    Clinical Lymphoma Myeloma & Leukemia, 2026

    DOI 10.1016/s2152-2650(26)01331-5 Source : OpenAlex

  10. MM-593: Phase 3 Randomized Study of Talquetamab + Daratumumab ± Pomalidomide vs Daratumumab + Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: MonumenTAL-3

    Clinical Lymphoma Myeloma & Leukemia, 2026

    DOI 10.1016/s2152-2650(26)02897-1 Source : OpenAlex

  11. PA-350 Phase 3, Randomized Study of Talquetamab (Tal) Plus Daratumumab (D) ± Pomalidomide (P) vs D Plus P and Dexamethasone (DPd) in Relapsed/Refractory Multiple Myeloma (RRMM): MonumenTAL-3

    Clinical Lymphoma Myeloma & Leukemia, 2026

    DOI 10.1016/s2152-2650(26)03713-4 Source : OpenAlex

  12. PHASE 3, RANDOMIZED STUDY OF TALQUETAMAB (TAL) PLUS DARATUMUMAB (DARA) ± POMALIDOMIDE (POM) VS DARA PLUS POM AND DEXAMETHASONE (DPD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): MONUMENTAL-3

    Hematology Transfusion and Cell Therapy, 2026

    DOI 10.1016/j.htct.2026.107913 Source : OpenAlex

  13. MAJESTEC-9: A PHASE 3 RANDOMIZED STUDY OF TECLISTAMAB MONOTHERAPY VS INVESTIGATOR’S CHOICE OF POMALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE OR CARFILZOMIB AND DEXAMETHASONE (PVD/KD) IN PATIENTS (PTS) WITH RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM)

    Hematology Transfusion and Cell Therapy, 2026

    DOI 10.1016/j.htct.2026.107889 Source : OpenAlex

  14. A complete response with daratumumab, venetoclax, azacitidine and dexamethasone in a heavily pre-treated, chemo-refractory early T-precursor acute lymphoblastic leukemia/lymphoma patient

    Annals of Hematology, 2025

    DOI 10.1007/s00277-024-06118-8 PMID 39847114 1 citation (Europe PMC) Source : OpenAlex

  15. When high dose methotrexate stops working, a successful bridge to transplant with TEDDI-R in a case of secondary CNS lymphoma

    Annals of Hematology, 2025

    DOI 10.1007/s00277-025-06285-2 PMID 40016397 Texte intégral en libre accèsSource : OpenAlex

  16. Myth or reality: Graft versus host disease after autologous hematopoietic cell transplantation, a multicentre experience

    Transplant Immunology, 2025

    DOI 10.1016/j.trim.2025.102286 PMID 40907722 Source : OpenAlex

  17. Successful treatment of steroid-refractory gastrointestinal GVHD with ruxolitinib in a patient after autologous stem cell transplantation: a case report

    International Journal of Hematology, 2025

    DOI 10.1007/s12185-025-04073-2 PMID 41004031 Source : OpenAlex

  18. Cutaneous cytomegalovirus infection: a case report

    Skin Health and Disease, 2025

    DOI 10.1093/skinhd/vzaf057 PMID 42222707 Texte intégral en libre accèsSource : OpenAlex

  19. Clinical Characteristics, Treatment Approaches, and Survival Predictors in Adult Acute Myeloid Leukemia: Interim Results from the Turkish Society of Hematology AML Registry

    Journal of Clinical Medicine, 2025

    DOI 10.3390/jcm14207367 PMID 41156238 Texte intégral en libre accèsSource : OpenAlex

  20. The Outcomes of Newly Diagnosed Multiple Myeloma Patients With Concurrent or Previous Solid Tumor History

    Clinical Lymphoma Myeloma & Leukemia, 2025

    DOI 10.1016/j.clml.2025.10.006 PMID 41206323 Source : OpenAlex

  21. Liposomal Amphotericin B-Induced Distal Renal Tubular Acidosis in a Patient with T-ALL and Febrile Neutropenia: A Diagnostic Challenge

    Research Square, 2025

    DOI 10.21203/rs.3.rs-6533569/v1 Texte intégral en libre accèsSource : OpenAlex

  22. AML-556: Personalized Therapy and Real-World Outcomes in Adult Acute Myeloid Leukemia: Lessons From a Nationwide Prospective Cohort in Turkey

    Clinical Lymphoma Myeloma & Leukemia, 2025

    DOI 10.1016/s2152-2650(25)01691-x Source : OpenAlex

  23. POSTER: AML-556 Personalized Therapy and Real-World Outcomes in Adult Acute Myeloid Leukemia: Lessons From a Nationwide Prospective Cohort in Turkey

    Clinical Lymphoma Myeloma & Leukemia, 2025

    DOI 10.1016/s2152-2650(25)00540-3 Source : OpenAlex

  24. Single agent vemurafenib or rituximab-vemurafenib combination for the treatment of relapsed/refractory hairy cell leukemia, a multicenter experience

    Leukemia Research, 2024

    DOI 10.1016/j.leukres.2024.107495 PMID 38599153 3 citations (Europe PMC) Source : OpenAlex

  25. Atypical presentation of PJP: hypercalcemia and kidney injury in an allogeneic stem cell transplant recipient

    BMC Infectious Diseases, 2024

    DOI 10.1186/s12879-024-10074-z PMID 39448907 1 citation (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  26. Original vs. Generic Plerixafor for the Mobilization of Stem Cells in Multiple Myeloma Patients

    Indian Journal of Hematology and Blood Transfusion, 2024

    DOI 10.1007/s12288-024-01841-8 PMID 39917490 Texte intégral en libre accèsSource : OpenAlex

  27. Azacitidine-related pyoderma gangrenosum

    Annales de Dermatologie et de Vénéréologie, 2024

    DOI 10.1016/j.annder.2024.103323 PMID 39488194 Source : OpenAlex

  28. Survival Outcomes of Patients with Primary Plasma Cell Leukemia in the Era of Proteasome Inhibitors and Immunomodulatory Agents: A Real-Life Multicenter Analysis

    Turkish Journal of Hematology, 2024

    DOI 10.4274/tjh.galenos.2024.2023.0450 PMID 39501735 2 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  29. Relapsed refractory multiple myeloma with CNS involvement successfully treated with Elranatamab: first reported case

    Frontiers in Immunology, 2023

    DOI 10.3389/fimmu.2023.1276295 PMID 37901215 18 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  30. Prospective Real-World Outcomes of Acute Myeloid Leukemia

    Blood, 2023

    DOI 10.1182/blood-2023-182800 Texte intégral en libre accèsSource : OpenAlex

  31. The Charlson Comorbidity Index Predicts Poor Prognosis in Elderly AML Patients

    AYBU AVESIS, 2023

    DOI 10.4999/uhod.236829 Source : OpenAlex

  32. Castleman Disease: A Multicenter Case Series from Turkey

    Turkish Journal of Hematology, 2022

    DOI 10.4274/tjh.galenos.2022.2021.0670 PMID 35176839 4 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  33. Analysis of factors associated with the development of myelofibrosis in polycythemia vera and essential thrombocythemia patients: a single-center experience

    Journal of Hematopathology, 2022

    DOI 10.1007/s12308-022-00488-6 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  34. A rare case of pulmonary lymphomatoid granulomatosis complicated with venous thrombosis.

    Sarcoidosis vasculitis and diffuse lung diseases, 2022

    DOI 10.36141/svdld.v38i4.10140 PMID 35115745 Texte intégral en libre accèsSource : OpenAlex

  35. Marjinal Zon Lenfoma Tanılı Hastalarda Klinik Özellikler ve Olası Prognostik Faktörler: İki Merkezden Retrospektif Analiz

    LLM Dergi, 2022

    DOI 10.5578/llm.20229903 Texte intégral en libre accèsSource : OpenAlex

  36. The impact of hematological parameters on survival for patients with COVID-19

    Ahi Evran Medical Journal, 2022

    DOI 10.46332/aemj.1014259 Texte intégral en libre accèsSource : OpenAlex

  37. Analysis of Demographic and Disease Characteristics of Patients with Chronic Myeloid Leukemia: A Single Centre Retrospective Analysis

    Acta Oncologica Turcica, 2022

    DOI 10.5505/aot.2022.08831 Texte intégral en libre accèsSource : OpenAlex

  38. Does blood type have an effect on the course of COVID-19?

    Sağlık Akademisi Kastamonu, 2022

    DOI 10.25279/sak.1014330 Texte intégral en libre accèsSource : OpenAlex

  39. Single Centre Experience: Bening and Malign Hematological Patients with COVID-19

    Sağlık Akademisi Kastamonu, 2022

    DOI 10.25279/sak.1061701 Texte intégral en libre accèsSource : OpenAlex

  40. Multiple Myeloma ve Plazma Hücreli Neoplaziler

    Akademisyen Kitabevi eBooks, 2022

    DOI 10.37609/akya.1210 Source : OpenAlex

  41. Hematolojide Güncel Yaklaşımlar

    Akademisyen Kitabevi eBooks, 2022

    DOI 10.37609/akya.1547 Texte intégral en libre accèsSource : OpenAlex

  42. Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies

    Turkish Journal of Hematology, 2021

    DOI 10.4274/tjh.galenos.2021.2021.0287 PMID 34521187 7 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  43. A Real-life Turkish Experience of Venetoclax Treatment in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia

    Clinical Lymphoma Myeloma & Leukemia, 2021

    DOI 10.1016/j.clml.2021.04.004 PMID 34059487 9 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  44. The outcome of COVID-19 in patients with hematological malignancy

    memo - Magazine of European Medical Oncology, 2021

    DOI 10.1007/s12254-021-00775-5 PMID 34904019 7 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  45. Hypercalcemia associated with the interaction between all trans retinoic acid and posaconazole in an acute promyelocytic leukemia case

    Journal of Oncology Pharmacy Practice, 2021

    DOI 10.1177/10781552211007889 PMID 33847196 6 citations (Europe PMC) Source : OpenAlex

  46. Vitreous hemorrhage: A rare ophthalmic adverse effect due to imatinib treatment

    Journal of Oncology Pharmacy Practice, 2021

    DOI 10.1177/10781552211060730 PMID 34775854 3 citations (Europe PMC) Source : OpenAlex

  47. RECURRENT AUTOIMMUNE HEMOLYTIC ANEMIA AFTER MRNA COVID-19 VACCINE (PFIZER-BIONTECH)

    Hematology Transfusion and Cell Therapy, 2021

    DOI 10.1016/j.htct.2021.10.1057 2 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  48. A RARE CASE: POSTTRANSPLANT NK/T CELL LYMPHOMA

    Hematology Transfusion and Cell Therapy, 2021

    DOI 10.1016/j.htct.2021.10.1033 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  49. CASE REPORT: FOLLICULAR LYMPHOMA PRESENTED WITH CHYLOTHORAX

    Hematology Transfusion and Cell Therapy, 2021

    DOI 10.1016/j.htct.2021.10.1039 2 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  50. The Prognostic Value of Blood Count Parameters in Patients with Diffuse Large B Cell Lymphoma

    Akdeniz Medical Journal, 2021

    DOI 10.17954/amj.2021.2566 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex